138 related articles for article (PubMed ID: 11851570)
21. New frontier of AIDS activism: international trade rules and global access to medicines. Interview by John S. James.
Sawyer E
AIDS Treat News; 1999 Apr; (No 317):1, 5-8. PubMed ID: 11366992
[TBL] [Abstract][Full Text] [Related]
22. GSK: please extend patent pool to AIDS drugs.
Douste-Blazy P; Bermudez J
Lancet; 2009 Apr; 373(9672):1339. PubMed ID: 19376450
[No Abstract] [Full Text] [Related]
23. Laboratory monitoring of HIV--after access to antiretroviral drugs, the next challenge for the developing world.
Tucker T; Yeats J
S Afr Med J; 2001 Aug; 91(8):615. PubMed ID: 11584766
[No Abstract] [Full Text] [Related]
24. Charity campaigns for drug companies to pool patents for newer HIV drugs.
Mayor S
BMJ; 2009 Oct; 339():b4056. PubMed ID: 19801380
[No Abstract] [Full Text] [Related]
25. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
26. Facilitating access of AIDS drugs while maintaining strong patent protection.
Ziker D
Duke Law Technol Rev; 2001 Dec; ():E1. PubMed ID: 15709282
[TBL] [Abstract][Full Text] [Related]
27. TRIPS: generic irony.
Howarth GR
Br J Gen Pract; 2002 Jan; 52(474):57. PubMed ID: 11791819
[No Abstract] [Full Text] [Related]
28. Canada to change patent law to allow export of cheap drugs.
Kondro W
Lancet; 2003 Oct; 362(9392):1290. PubMed ID: 14577437
[No Abstract] [Full Text] [Related]
29. The missing ingredient in medicine patent pools.
Gold ER; Morin JF
Lancet; 2009 Oct; 374(9698):1329-30. PubMed ID: 19837251
[No Abstract] [Full Text] [Related]
30. Compulsory licenses and access to HIV/AIDS drugs.
Zuniga JM; Wilder R
IAPAC Mon; 2001 Dec; 7(12):328-32. PubMed ID: 11799944
[No Abstract] [Full Text] [Related]
31. Essential AIDS medications in India.
Thomas J
Issues Med Ethics; 2000; 8(2):62. PubMed ID: 16323350
[No Abstract] [Full Text] [Related]
32. Global health and university patents.
Kapczynski A; Crone ET; Merson M
Science; 2003 Sep; 301(5640):1629. PubMed ID: 14500943
[No Abstract] [Full Text] [Related]
33. Balancing pills and patents: intellectual property and the HIV/AIDS crisis.
Nderitu T
E Law; 2001 Sep; 8(3):E5. PubMed ID: 16903022
[No Abstract] [Full Text] [Related]
34. Hope for South Africa--at last.
Lancet; 2003 Aug; 362(9383):501. PubMed ID: 12932376
[No Abstract] [Full Text] [Related]
35. World CAB meets with Gilead.
Huff B
GMHC Treat Issues; 2006; 20(4-7):6-8. PubMed ID: 17228449
[No Abstract] [Full Text] [Related]
36. Intellectual property rights, market competition and access to affordable antiretrovirals.
Pascual F
Antivir Ther; 2014; 19 Suppl 3():57-67. PubMed ID: 25309984
[TBL] [Abstract][Full Text] [Related]
37. Experts clash over likely impact of cheap AIDS drugs in Africa.
Wadman M
Nature; 2001 Apr; 410(6829):615-6. PubMed ID: 11287906
[No Abstract] [Full Text] [Related]
38. World Trade Organization still threatens supply of affordable AIDS drugs.
Hagmann M
Bull World Health Organ; 2002; 80(9):762-3. PubMed ID: 12378300
[No Abstract] [Full Text] [Related]
39. Competition body rules that drug companies "abused" their position.
Sidley P
BMJ; 2003 Oct; 327(7421):946. PubMed ID: 14576226
[No Abstract] [Full Text] [Related]
40. Improving access to essential drugs for people living with HIV/AIDS.
Balasubramaniam K
Issues Med Ethics; 2000; 8(1):26-7. PubMed ID: 16323335
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
